Non-exclusive drug discount agreement for Lisdexamfetamine, excluding hard capsules size 30
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Lisdexamfetamin, exklusive Hartkapseln/Kapseln mit der Packungsgröße 30 Stück
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No minimum quantity commitment; actual demand depends on prescription behavior and patient numbers.
Buyer may terminate open-house if exclusive agreements are concluded, typically 8-12 months after publication.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Jan 31, 2028
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jan 2028
- Supply of Lisdexamfetamine pharmaceutical products (excluding hard capsules size 30)
- Non-exclusive discount agreement under German Social Code (SGB V §130a Abs. 8)
Show full summary
Non-exclusive drug discount agreement for Lisdexamfetamine (ATC N06BA12) via open-house model for AOK PLUS covering Saxony and Thuringia. No estimated value; no guaranteed minimum purchase; contract ends by 31.01.2028. Submission period starts 05.01.2026 and continues periodically.
Risks
No minimum quantity commitment; actual demand depends on prescription behavior and patient numbers.
Buyer may terminate open-house if exclusive agreements are concluded, typically 8-12 months after publication.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Participation open to all pharmaceutical enterprises meeting eligibility criteria
Administrative
- Submission via DTVP portal; access requires prior request
- Strict confidentiality of tender documents and discount terms
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive drug discount agreement for Lisdexamfetamine, excluding hard capsules size 30
Supply of Lisdexamfetamine pharmaceutical products under non-exclusive discount agreement with AOK PLUS. No minimum quantity guaranteed. Open to all eligible pharmaceutical enterprises.
Location
Duration
Category
Award Criteria
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Lisdexamfetamin, exklusive Hartkapseln/Kapseln mit der Packungsgröße 30 Stück
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 03 Dec 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 806651-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No minimum quantity commitment; actual demand depends on prescription behavior and patient numbers.
Buyer may terminate open-house if exclusive agreements are concluded, typically 8-12 months after publication.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications